Cas:852691-03-3 ethyl 1-tert-butyl-5-(trifluoromethyl)pyrazole-4-carboxylate manufacturer & supplier

We serve Chemical Name:ethyl 1-tert-butyl-5-(trifluoromethyl)pyrazole-4-carboxylate CAS:852691-03-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

ethyl 1-tert-butyl-5-(trifluoromethyl)pyrazole-4-carboxylate

Chemical Name:ethyl 1-tert-butyl-5-(trifluoromethyl)pyrazole-4-carboxylate
CAS.NO:852691-03-3
Synonyms:1-tert-butyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl ester;Ethyl 1-(tert-butyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate
Molecular Formula:C11H15F3N2O2
Molecular Weight:264.24400
HS Code:2933199090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:44.12000
Exact Mass:264.10900
LogP:2.83360

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1-tert-butyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl 1-(tert-butyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl 1-(tert-butyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate Use and application,1-tert-butyl-5-trifluoromethyl-1H-pyrazole-4-carboxylic acid ethyl ester technical grade,usp/ep/jp grade.


Related News: Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.” Ethenesulfonic acid, sodium salt, polymer with 2-propenenitrile, hydrolyzed manufacturers Zynteglo was granted conditional marketing authorisation in May 2019. The conditional authorisation means that there is more evidence to come about the medicine, which the company will provide. EMA regularly reviews new information that becomes available. 3-(2-Amino-1-methylsulfanyl-ethyl)-2-hydroxy-3H-pyrimidin-4-one; hydrochloride suppliers Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.” 5-methyl-N2-(1-methyl-1H-indol-5-yl)-N4-(2-methylbenzyl)pyrimidine-2,4-diamine vendor & factory Denise Bowser, commercial director at Onyx, commented, “Over the years, we have worked towards building a strong reputation in helping drug developers with complex chemistry. ,The Company most recently announced plans to establish a dedicated laboratory space with Biosafety Level-3 (BSL-3) containment to handle testing of SARS-CoV-2 (the viral strain causing COVID-19) and other similar pathogens that cause human disease.